New molecules called selective androgen receptor degraders (SARDs) might be helpful in fighting advanced prostate cancer, according to an industry-sponsored study presented April 1, at the 99th annual meeting of the Endocrine Society. "If successful in the clinic, the novel highly potent SARDs discovered in this program could be used to treat many of the [...]
Fetal estrogen estetrol, also called E4, is being tested in the Netherlands as a treatment for advanced prostate cancer. "E4 for the treatment of prostate cancer would offer a new and affordable option compared to current standard and new therapies. An important advantage of E4 is expected to be the avoidance of the hypoestrogenic side [...]
Researchers from the University and the Sichuan Antibiotics Industrial Institute in China have discovered a novel treatment for advanced prostate cancer. For over forty years, ADT has been the foundation of advanced stage prostate cancer treatment. ADT is effective initially, most often measured by a drop in PSA measurement. But in almost all cases, prostate [...]
There’s a better way to do a PET scan, by using radiotracer fluciclovine (fluorine-18; F-18) (Journal of Nuclear Medicine, March 2017) According to researcher Ashesh B. Jani, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, fluciclovine can improve imaging in recurrent prostate cancer patients with no additional radiation side effects. An improved PET [...]
There's a new Phase 3 clinical trial for an oral medication, taken one time per day, that will reduce testosterone for advanced prostate cancer. Myovant Sciences is testing their new drug, called Relugolix in a trial called, HERO. Relugolix lowers testosterone by inhibiting pituitary release of luteinizing hormone and follicle-stimulating hormone. Todays testosterone reducing therapies require injections and [...]